Neovascular (wet) age-related macular degeneration (AMD)

Active Ingredient: Pegaptanib

Indication for Pegaptanib

Population group: only adults (18 years old or older)

Pegaptanib is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) in adults.

For this indication, competent medicine agencies globally authorize below treatments:

0.3 mg once every 6 weeks

For:

Dosage regimens

Intravitreal, 0.3 milligrams pegaptanib, once every 42 days.

Detailed description

The patient’s medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure.

The recommended dose is 0.3 mg pegaptanib, equivalent to 90 microliters, administered once every six weeks (9 injections per year) by intravitreal injection into the affected eye.

Following the injection, transient increases in intraocular pressure were seen in pegaptanib treated patients. Therefore, the perfusion of the optic nerve head and intraocular pressure should be monitored. Moreover patients should be closely monitored for vitreous haemorrhage and endophthalmitis in the two weeks following the injection. Patients should be instructed to report any symptoms suggestive of these conditions without delay.

After 2 consecutive injections of pegaptanib, if a patient does not demonstrate a treatment benefit (loss of less than 15 letters of visual acuity) at the 12-week visit, consideration should be given to stopping or withholding pegaptanib therapy.

Dosage considerations

For intravitreal injection use only.

Active ingredient

Pegaptanib

Pegaptanib is a pegylated modified oligonucleotide that binds with high specificity and affinity to extracellular Vascular Endothelial Growth Factor (VEGF165) inhibiting its activity. VEGF is a secreted protein that induces angiogenesis, vascular permeability and inflammation, all of which are thought to contribute to the progression of the neovascular (wet) form of AMD.

Read more about Pegaptanib

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.